Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Maintenance treatment with antipsychotic drugs for schizophrenia

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD008016.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 16 May 2012see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Schizophrenia Group

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Stefan Leucht

    Correspondence to: Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany

    [email protected]

  • Magdolna Tardy

    Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany

  • Katja Komossa

    Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie, Technische Universität München, Klinikum rechts der Isar, München, Germany

  • Stephan Heres

    Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany

  • Werner Kissling

    Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany

  • John M Davis

    University of Illinois at Chicago, Chicago, USA

Contributions of authors

Stefan Leucht: designing the review, study selection, data extraction, statistical analysis and writing of the report.
Magdolna Tardy: designing the review, study selection, data extraction, statistical analysis and writing of the report.
Katja Komossa: designing the study, study selection, data extraction and writing of the report.
Stephan Heres: designing the study, data extraction and writing of the report.
Werner Kissling: designing the study, data extraction and writing of the report.
John Davis: designing the study, data extraction, statistical analysis and writing of the report.

All authors have agreed to a co‐publication of this review in the Lancet (Leucht 2012).

Sources of support

Internal sources

  • Freistaat Bayern, Germany.

  • Psychiatric Institute, University of Chicago at Illinois, USA.

External sources

  • Bundesministerium für Bildung und Forschung Grant number 01KG0816 88166528, Germany.

Declarations of interest

Stefan Leucht: has received honoraria for consulting/advisory boards from Alkermes, Bristol‐Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Medavante and Roche; lecture honoraria from AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, Essex Pharma, Janssen, Johnson & Johnson, Lundbeck Institute, Pfizer and Sanofi‐Aventis; and Eli Lilly has provided medication for a trial with SL as the primary investigator.
Magdolna Tardy: none to declare.
Katja Komossa: none to declare.
Stephan Heres: received honoraria from Janssen‐Cilag, Sanofi‐Aventis and Johnson & Johnson. SH has accepted travel or hospitality payment from Janssen‐Cilag, Sanofi‐Aventis, Johnson & Johnson, Pfizer, Bristol‐Myers Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly.
Werner Kissling: has received honoraria for board memberships, consulting and lectures from Janssen and Eli Lilly; honoraria for development of educational materials from Janssen; grant support from Janssen and AstraZeneca; and travel/accommodation expenses from AstraZeneca, Eli Lilly and Janssen.
John M Davis: none to declare.

Acknowledgements

We thank the editorial team of the Cochrane Schizophrenia Group for its enormous support. We thank Richard Skodnek, MD, for his work on a preliminary version of this review. We also thank Astellas, Bristol MyersSquibb, EliLilly, Lundbeck, Pfizer, Johnson & Johnson, SanofiAventis, Eric Chen, George Gardos, Julian Leff, and Erik Denys for sending additional information on their studies. We thank Michael Borenstein and Georgia Salanti for their statistical advice and for conducting statistical analyses.
The Cochrane Schizophrenia Group Editorial Base in Nottingham, UK, produces and maintains standard text for use in the Methods section of their reviews. We have used some of this text as the basis of what appears here and adapted it as required.

Version history

Published

Title

Stage

Authors

Version

2020 Aug 11

Maintenance treatment with antipsychotic drugs for schizophrenia

Review

Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht

https://doi.org/10.1002/14651858.CD008016.pub3

2012 May 16

Maintenance treatment with antipsychotic drugs for schizophrenia

Review

Stefan Leucht, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis

https://doi.org/10.1002/14651858.CD008016.pub2

2009 Oct 07

Maintenance treatment with antipsychotic drugs for schizophrenia

Protocol

Katja Komossa, Anna M Depping, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht

https://doi.org/10.1002/14651858.CD008016

Differences between protocol and review

Instead of Stata 2002 we used Comprehensive Meta‐analysis Version 2 (Borenstein 2006) for the meta‐regression, but both programs use the same formulae. NNTB and NNTH were calculated as the inverse of the risk difference rather than using Visual Rx. Various subgroup and meta‐regression analyses were added and the method section on the investigation of heterogeneity changed to reflect this. Post‐hoc analyses were clearly marked as such using an asterisk*.
We only contacted the manufacturers of so‐called second‐generation antipsychotic drugs for further trials (Sanofi‐Aventis, Astellas, Bristol‐Myers Squibb, Novartis, Eli Lilly, AstraZeneca, Janssen‐Cilag, Lundbeck and Pfizer; asenapine, iloperidone and lurasidone were not available at the time of our first search and therefore not contacted). Our attempts to contact the manufacturers of old "first‐generation antipsychotic drugs" had not been successful and most of these trials had been published more than 15 years ago (the official time trial documents must be stored in many countries).

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.